16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.
Glaxosmithkline
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
Wake Forest University
Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor.
Ucla and The Wadsworth Veterans Administration Hospital
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2).
Pfizer
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).
Pharmacia
Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter.
University of Maryland
Recent advances in steroid amino acid conjugates: Old scaffolds with new dimensions.
Panjab University
Synthesis and biological evaluation of novel steroidal pyrazoles as substrates for bile acid transporters.
Xenoport
A novel class of apical sodium-dependent bile acid transporter inhibitors: the amphiphilic 4-oxo-1-phenyl-1,4-dihydroquinoline derivatives.
Sankyo
A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 1,2-benzothiazepines.
Pfizer
A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 2,3-disubstituted-4-phenylquinolines.
Searle Discovery
Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
Ardelyx
Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof
Industry Academic Cooperation Foundation Keimyung University
Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
Boehringer Ingelheim International